Feature | April 13, 2012

GE Healthcare Amyloid Plaque PET Agent Has Promising Phase 3 Results

All studies meet primary endpoints, full results to be reported later this year

April 13, 2012 — GE Healthcare announced the preliminary results of two Phase 3 studies of its investigational positron emission tomography (PET) amyloid imaging agent, F-18 flutemetamol, where both studies met their primary endpoints. One study, in terminally ill patients who agreed to undergo brain autopsy, showed strong concordance between flutemetamol PET images and Alzheimer’s disease-associated beta amyloid brain pathology. The other study, in young healthy volunteers under age 40, had results concordant with the known lack of brain amyloid in this population. Full results of these studies will be presented in the coming months. 

“The ability to detect or exclude significant amyloid deposits in the brain, along with other diagnostic tests, may help physicians make a more accurate assessment of patients with suspected Alzheimer’s disease (AD) and other cognitive disorders. The results from these studies are quite encouraging in demonstrating the potential of flutemetamol in that regard,” said Carl Sadowsky, M.D., clinical professor of neurology at Nova Southeastern University, Ft. Lauderdale, Fla. “We need an accurate diagnosis and better treatment, as accurate diagnosis has the potential to enable better patient management, and may also save cost.”

The accumulation of beta amyloid in the brain is believed to play a role leading up to the degeneration of neurons in AD and is one of several pathological characteristics implicated in the development of AD. Currently, AD is confirmed by histopathological identification of core features, including beta amyloid plaques, in post-mortem brain samples. Targeted amyloid imaging agents are being studied to determine their ability to help physicians detect amyloid deposition in living humans.

“Flutemetamol may well prove to be a clinically valuable component of a broader diagnostic workup that neurologists use when assessing patients with cognitive impairments, who may have AD,” said Jonathan Allis, MI (molecular imaging) PET segment leader, GE Healthcare Medical Diagnostics. “These studies support our application for regulatory approval of flutemetamol, and we intend to file later this year.”

Flutemetamol is a GE Healthcare PET imaging agent in development for the detection of beta amyloid, and is part of a portfolio of diagnostic solutions the company is currently developing in the Alzheimer’s field. GE Healthcare is taking a comprehensive approach to understanding AD through its ongoing research to uncover the causes, risks and physical effects of the disease. For example, the company is partnering with pharma to identify a biosignature, or a biological indicator, which may help physicians diagnose AD prior to the onset of clinical symptoms.

Earlier this week, the U.S. Food and Drug Administration (FDA) approved the first diagnostic agent to image Alzheimer’s disease beta-amyloid neuritic plaques in the living brain. Eli Lilly and Company and Avid Radiopharmaceuticals Inc., a wholly owned subsidiary of Lilly, released florbetapir (Amyvid), a positron emission tomography (PET) radioactive tracer agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.

For more information: www.gehealthcare.com

Related Content

18F-DCFBC PET/CT
News | Prostate Cancer| August 21, 2015
August 21, 2015 — A molecular imaging biomarker is able to detect fast-growing primary prostate cancer and distinguis
biomarkers, Alzheimer's disease, AD, MRI, PET, University of Kentucky, Sanders-Brown Center on Aging
News | Neuro Imaging| July 31, 2015
Researchers at the University of Kentucky’s Sanders-Brown Center on Aging are on the hunt for biomarkers that might...
nuclear medicine diagnostic market, North America, PET, SPECT, Mordor
News | Molecular Imaging| June 29, 2015
The Global Nuclear Medicine Diagnostics Market report from Mordor Intelligence revealed that North America accounts for...
News | Molecular Imaging| June 12, 2015
A first-in-human study shows how a powerful new drug finds and attaches itself to the ovarian and prostate cancer cells...
PET, neuroinflammation, C-11 PBR28, dementia, SNMMI 2015
News | June 12, 2015
Neuroinflammation caused by a reactive immune system could be tripping off the neurodegeneration seen in certain...
Siemens, Blue Earth Diagnostics, PET/CT, U.S. agreement, PETNET
News | June 12, 2015
Siemens’ PETNET Solutions Inc. has entered into a nationwide agreement with U.K.-based Blue Earth Diagnostics Ltd....
PET, PSMA, radiotracer, SNMMI 2015, prostate cancer
Feature | June 12, 2015
A new molecular imaging agent has been demonstrated to find prostate cancer that has spread to other tissues by locking...
Siemens, SNMMI 2015, Biograph RT Pro, Symbia Evo, syngo.via for MI
News | June 11, 2015
At the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 6-10 at the Baltimore...
GE Healthcare, FASTlab 2, FDG Duo, GENtrace cyclotron, PET imaging

FASTlab 2 with FDG Duo cassette image courtesy of GE Healthcare

Technology | June 08, 2015
GE Healthcare announced that it has created a solution to make positron emission tomography (PET) tracers for...
Ipsen, OctreoPharm Sciences, acquisition, NET, radioactive-labeled compound
News | May 27, 2015
Ipsen announced the signature of an agreement to acquire OctreoPharm Sciences, a private German life sciences company...
Overlay Init